# Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer

> **NCT02981719** · NA · COMPLETED · sponsor: **Fuda Cancer Hospital, Guangzhou** · enrollment: 61 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **PROCEDURE:** simultaneous gemcitabine and irreversible electroporation
- **PROCEDURE:** irreversible electroporation

## Key facts

- **NCT ID:** NCT02981719
- **Lead sponsor:** Fuda Cancer Hospital, Guangzhou
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-01
- **Primary completion:** 2018-10-01
- **Final completion:** 2020-10-01
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02981719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02981719, "Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT02981719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*